These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1286 related items for PubMed ID: 28899625

  • 1. Cost-effectiveness of HPV vaccination in the context of high cervical cancer incidence and low screening coverage.
    Võrno T, Lutsar K, Uusküla A, Padrik L, Raud T, Reile R, Nahkur O, Kiivet RA.
    Vaccine; 2017 Nov 01; 35(46):6329-6335. PubMed ID: 28899625
    [Abstract] [Full Text] [Related]

  • 2. Cost-effectiveness of the prophylactic HPV vaccine: an application to the Netherlands taking non-cervical cancers and cross-protection into account.
    Luttjeboer J, Westra TA, Wilschut JC, Nijman HW, Daemen T, Postma MJ.
    Vaccine; 2013 Aug 20; 31(37):3922-7. PubMed ID: 23806241
    [Abstract] [Full Text] [Related]

  • 3. Cost-effectiveness analysis of the introduction of the human papillomavirus vaccine in Honduras.
    Aguilar IB, Mendoza LO, García O, Díaz I, Figueroa J, Duarte RM, Perdomo G, Garcia AG, Janusz CB.
    Vaccine; 2015 May 07; 33 Suppl 1():A167-73. PubMed ID: 25919157
    [Abstract] [Full Text] [Related]

  • 4. Estimating the cost-effectiveness profile of a universal vaccination programme with a nine-valent HPV vaccine in Austria.
    Boiron L, Joura E, Largeron N, Prager B, Uhart M.
    BMC Infect Dis; 2016 Apr 16; 16():153. PubMed ID: 27084683
    [Abstract] [Full Text] [Related]

  • 5. Clinical and economic impact of school-based nonavalent human papillomavirus vaccine on women in Singapore: a transmission dynamic mathematical model analysis.
    Tay SK, Hsu TY, Pavelyev A, Walia A, Kulkarni AS.
    BJOG; 2018 Mar 16; 125(4):478-486. PubMed ID: 29266694
    [Abstract] [Full Text] [Related]

  • 6. Prophylaxis of cervical cancer and related cervical disease: a review of the cost-effectiveness of vaccination against oncogenic HPV types.
    Armstrong EP.
    J Manag Care Pharm; 2010 Apr 16; 16(3):217-30. PubMed ID: 20331326
    [Abstract] [Full Text] [Related]

  • 7. Cost-effectiveness analysis of adding a quadrivalent HPV vaccine to the cervical cancer screening programme in Switzerland.
    Szucs TD, Largeron N, Dedes KJ, Rafia R, Bénard S.
    Curr Med Res Opin; 2008 May 16; 24(5):1473-83. PubMed ID: 18413014
    [Abstract] [Full Text] [Related]

  • 8. Incremental cost-effectiveness evaluation of vaccinating girls against cervical cancer pre- and post-sexual debut in Belgium.
    Demarteau N, Van Kriekinge G, Simon P.
    Vaccine; 2013 Aug 20; 31(37):3962-71. PubMed ID: 23777952
    [Abstract] [Full Text] [Related]

  • 9. Comparative cost-effectiveness of the quadrivalent and bivalent human papillomavirus vaccines: a transmission-dynamic modeling study.
    Brisson M, Laprise JF, Drolet M, Van de Velde N, Franco EL, Kliewer EV, Ogilvie G, Deeks SL, Boily MC.
    Vaccine; 2013 Aug 20; 31(37):3863-71. PubMed ID: 23830974
    [Abstract] [Full Text] [Related]

  • 10. Public health impact and cost-effectiveness of switching from bivalent to nonavalent vaccine for human papillomavirus in Norway: incorporating the full health impact of all HPV-related diseases.
    Diakite I, Nguyen S, Sabale U, Pavelyev A, Saxena K, Tajik AA, Wang W, Palmer C.
    J Med Econ; 2023 Aug 20; 26(1):1085-1098. PubMed ID: 37608730
    [Abstract] [Full Text] [Related]

  • 11. Cost-effectiveness of different human papillomavirus vaccines in Singapore.
    Lee VJ, Tay SK, Teoh YL, Tok MY.
    BMC Public Health; 2011 Mar 31; 11():203. PubMed ID: 21453537
    [Abstract] [Full Text] [Related]

  • 12. Cost-effectiveness evaluation of a quadrivalent human papillomavirus vaccine in Belgium.
    Annemans L, Rémy V, Oyee J, Largeron N.
    Pharmacoeconomics; 2009 Mar 31; 27(3):231-45. PubMed ID: 19354343
    [Abstract] [Full Text] [Related]

  • 13. Cost-effectiveness analysis of introducing universal human papillomavirus vaccination of girls aged 11 years into the National Immunization Program in Brazil.
    Novaes HM, de Soárez PC, Silva GA, Ayres A, Itria A, Rama CH, Sartori AM, Clark AD, Resch S.
    Vaccine; 2015 May 07; 33 Suppl 1():A135-42. PubMed ID: 25919154
    [Abstract] [Full Text] [Related]

  • 14. Cost-Effectiveness Analysis of Human Papillomavirus Vaccination in Adolescent Girls in Taiwan.
    Tang CH, Cheng WF, Jiang JH, You SL, Huang LW, Hsieh JY, Mukherjee P, Van Kriekinge G, Lee C.
    Asian Pac J Cancer Prev; 2019 May 25; 20(5):1377-1387. PubMed ID: 31127896
    [Abstract] [Full Text] [Related]

  • 15. Public health impact and cost effectiveness of routine and catch-up vaccination of girls and women with a nine-valent HPV vaccine in Japan: a model-based study.
    Cody P, Tobe K, Abe M, Elbasha EH.
    BMC Infect Dis; 2021 Jan 06; 21(1):11. PubMed ID: 33407188
    [Abstract] [Full Text] [Related]

  • 16. Potential impact of a nonavalent HPV vaccine on the occurrence of HPV-related diseases in France.
    Riethmuller D, Jacquard AC, Lacau St Guily J, Aubin F, Carcopino X, Pradat P, Dahlab A, Prétet JL.
    BMC Public Health; 2015 May 02; 15():453. PubMed ID: 25934423
    [Abstract] [Full Text] [Related]

  • 17. Epidemiological dynamic modeling of human papillomavirus-related diseases to assess vaccination strategies in Argentina.
    Borracci RA, Segal SV, Méndez JH.
    Medicina (B Aires); 2018 May 02; 78(5):315-328. PubMed ID: 30285924
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Cost-effectiveness analysis of human papillomavirus vaccination in South Africa accounting for human immunodeficiency virus prevalence.
    Li X, Stander MP, Van Kriekinge G, Demarteau N.
    BMC Infect Dis; 2015 Dec 11; 15():566. PubMed ID: 26652918
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 65.